Burden of Herpes Zoster in Adult Patients with Underlying Conditions: Analysis of German Claims Data, 2007–2018

The study uses a retrospective, matched cohort design and has been conducted in accordance with applicable subject privacy requirements and the guiding principles of the Declaration of Helsinki of 1964. The analysis was based on secondary claims data and, as such, consultation with an ethics committee was not required, in line with the national guidelines “Good Practice Secondary Data Analysis” [21] and the STROSA standard for “Standardized Reporting of Secondary Data Analyses” [22].

Yearly results were computed from 2008 to 2018. Information from 2007 was used to exclude prevalent HZ cases in the first year under study. In the first analysis, we investigated whether individuals with UC are more at risk to develop HZ. Hence, the main goal was to compare HZ incidence in a cohort of patients with an UC and a cohort of patients without any of the UCs under investigation. Exact matching was used to account for differences in the distribution of age and sex between the cohorts. Odds ratios (ORs) were computed and reported on a yearly basis. To identify the marginal effect of each UC, two different strategies were used. The main analysis used data from all patients and accounted for multi-morbidity using a logistic regression model with incident HZ as the dependent variable and dummies for each UC and age as covariates. Hence, the effect of each UC is quantifiable even if multiple UCs are present in the same patient. A sensitivity analysis was performed using data from patients who had exactly one of the UCs under study.

In the second analysis, the recurrence rates of HZ in patients with and without UCs were estimated.

A cohort of patients who were initially identified to have an acute HZ in 2008 were followed, and any additional episodes of acute HZ in at least two quarters of a year following the initial diagnosis were counted. The patients were followed up until leaving SHI, death, or until the end of 2018. Leaving SHI and death resulted in censored observations. The data were used to compute the cumulative probability of experiencing HZ recurrences, as well as the mean time to recurrence.

Analyses were based on claims data from one of the largest German SHI, BARMER, and cover the time period 2007–2018.² The BARMER “Wissenschaftliches Data-Warehouse” (W-DWH) accounts for approximately 9 million people, or 13% of the SHI population in Germany, and is managed with utmost respect to data cleaning and quality by BARMER. The SHI population represents about 87% of the population living in Germany [12]. Based on comparison with published data from KM6 statistics, the data set is representative of the German SHI population in terms of age and gender distribution [23]. Diagnostic data include all diagnoses documented during physician outpatient contacts and patient hospital stays. Laboratory or clinical parameters were not included. A general description of the claim database in the German setting can be found in Swart et al. [24].

For all analyses, patients aged 18 years or older in the year under study were included. Not included were patients who were originally insured with Deutsche BKK (approx. 10% of all current BARMER insured), a SHI which merged with BARMER in 2017, because there were insufficient data on those patients for analysis. For privacy reasons, the W-DWH only provides the year of birth and, hence, age was computed as the difference between the year under study and the year of birth. Based on the structure of (potential) German disease management programs (DMPs) [25, 26] and in consultation with a medical expert panel, the following UCs with the corresponding International Classification of Diseases (ICD), Tenth Revision, German Modification (ICD-10-GM) diagnosis codes were defined as potential risks: asthma (code J45), chronic heart failure (CHF; code I50), COPD (codes J44, J96), coronary heart disease (CHD; codes I20, I21, I22, I25), diabetes mellitus type 1 (DMT1; code E10), diabetes mellitus type 2 (DMT2; code E11), depression (code F32, F33, F34), and RA (codes M05, M06).

An individual was identified as belonging to a potential group with an UC if an established diagnois was documented for either an inpatient or an outpatient in two of the four quarters of a study year. A patient could belong to multiple UC groups. For incidence analyses, the UC needed to be present in the year under consideration. In addition, only patients who were observable (i.e., insured) in all four quarters of the year under study were included, which excludes patients who died or left SHI in that year. For estimating recurrence, the UC needed to be present in the year of the initial HZ diagnosis.

A HZ case was defined as at least one diagnosis of ICD-10-GM code B02 in either an in- or outpatient setting in the year under study, and a corresponding prescription of an antiviral drug (Anatomical Therapeutic Chemical [ATC] codes: D06BB03, J05AB11, J05AB09, J05AB15, J05AB01, S01AD07, S01AD03). As diagnosis is only reported on a quarterly basis, a case is only counted when the prescription is given in the same quarter. For the analysis of HZ recurrence, ICD code B02.2 (PHN) was excluded to focus only on acute recurrences. The time to recurrence was measured in quarters of a year.

The sizes of the cohorts for each year are shown in Table 1. Beginning with the adult population covered in the SHI, which is larger than 7 million for each year, all patients with UCs were identified. The number of patients with UCs ranged from 1.8 million in 2008 to 2.3 million in 2018. These patients were matched to controls without UCs. The average age of the cohort with an UC was 63 years, while the average age of the cohort without an UC was 61 years. An almost perfect balance was achieved in terms of the sex ratio, with each cohort comprising approximately 63% females over the total observational period. There is a slight increase in the average number of UCs under study per patient from 2008 to 2018, increasing from 1.4 in 2008 to 1.5 in 2018. The incidence of HZ in the data varies across age groups, with a higher incidence observed for older populations. The incidences are stable over time, but there is a positive shift in incidences for the cohort with UC when compared to the controls (see also Electronic Supplementary Material [ESM] Table S5). Based on the most recent data from 2018, an incidence of 3.9 per 1000 PY was observed for the age group 18–49 years if no UCs were present but for patients with UCs the incidence was 5.3 per 1000 PY; for the age group 50–59 years, the incidences were 5.4 and 7.1 per 1000 PY, respectively. In the oldest age group, comprising persons aged 60 years or older, the incidence was 8.2 per 1000 PY for those without UCs and 9.7 per 1000 PY for the cohort with UCs.

The main results of the analysis are shown in Fig. 1, which presents the OR estimates for each UC for the three age groups: 18–49 years, 50–59 years, and 60 years and older. The boxplots show the variability in the 11 OR estimates within each age group, one for each year under study. The ORs for most UCs are significantly higher than 1 in each year, and the variation in OR estimates over the years is small (ESM Tables S1–S4). It can be seen that RA has the highest OR, around 1.5, for most years. Excluding diabetes and CHF, the other conditions (i.e., asthma, COPD, CHD, and depression) have ORs falling in the range 1.1–1.3 for most years, which translates into a 10–30% increase in the odds of an acute HZ when compared to a person with none of these UCs (ESM Table S1). For both types of diabetes (DMT1, DMT2), ORs > 1 were observed in the youngest age group (18–49 years) (ESM Table S2). Additionally, for all UCs, the OR is highest in the youngest age group (Fig. 1; ESM Tables S2–S4).

In the subgroup analysis, asthma and COPD patients were stratified according to those with no prescription or those with a prescription of at least one systemic corticosteroid throughout the year under study. The results of this analysis highlight that asthma patients who receive systemic corticosteroid medication had a higher HZ risk than patients who do not receive the medication. We observed the same effect for COPD patients in the older age groups, but not for patients aged 49 years and younger (Fig. 2).

We repeated the analysis for patients with exactly one UC, which resulted in a smaller sample size and cohorts that were, on average, younger than those in the main analysis. The results are shown in Fig. 3 for the whole population (aged 18 years and older). While the ORs are, on average, higher than in the main analysis, RA, asthma, and depression remain the conditions with the highest ORs. With the exceptions of DMT1, DMT2, and CHF, the ORs for all UCs were significantly higher than 1 for each study year.

In this study, 43,003 patients met the inclusion criteria for the analysis of HZ recurrence (i.e., incident HZ diagnosis in 2008), of whom 9.6% (n = 4141) were observed to have at least one case of recurrent HZ from 2009 to 2018. Of these 4141 patients, 25% (n = 1030) experienced at least a second recurrence during this time period. As shown in Fig. 4, 0.6–1.2% of all patients experienced more than two recurrences, depending on their age. The observed mean time to first recurrence was 4.7 years.

The resulting estimates of the cumulative HZ recurrence curves are shown in Fig. 5. The patient group with the highest risk of recurrence is that comprising patients aged less than 50 years old with at least one UC as, on average, more than 15% of these patients had experienced at least one recurrence at the end of the follow-up period; the group of patients aged 50–59 years had the second highest risk of recurrence, regardless of UC status. The group with the lowest risk of recurrence comprised patients aged 60 years and older, whose cumulative probability of recurrence was between 5 and 10%.

In addition, the risk of experiencing a second HZ recurrence was higher than the risk of an initial recurrence (Fig. 6). For the incident HZ, patients aged less than 50 years who had already experienced one recurrence had a 40% probability of experiencing another recurrence.

Using German claims data, we have conducted an analysis of patients with HZ and assessed their risk for a recurrence in relation to UCs. The results indicate that patients with either asthma, CHD, COPD, depression, or RA had an increased risk of developing an acute HZ compared to patients without any of the UCs under study. RA had the highest OR among these conditions, varying from 1.37 to 1.57 for all age groups, and patients with depression also showed a significantly higher risk of developing HZ in all age groups. When the data were adjusted for systemic corticosteroid therapy in patients with asthma and COPD, the risk for an acute HZ was higher in those using systemic corticosteroid than in those who were not. Analysis of recurrence indicated that patients with at least one UC in the age groups 18–49 years and 50–59 years had the highest risk for a recurrent HZ. Regardless of age groups, the risk of developing a second recurrence was two- to threefold higher as compared to the risk of developing a first recurrence.

Multiple studies have related UCs to an increased risk of HZ [13, 16, 17, 33‐47]. In addition, a recent meta-analysis showed robust associations between HZ and UCs across 88 studies [48]. The present study corroborates these results. The related risk for HZ can be explained by the diseases themselves and their underlying biological mechanisms, as well as by specific immunosuppressive drug treatment.

Our results on the effect of RA on HZ are consistent with those reported from other studies. A case–control study from the UK using primary clinical practice data reported an OR very similar to the results of the present study (OR 1.46) [13]. In RA, it is not only the general impairment of the immune system that is associated with an increased risk for infectious diseases, but the disease activity of RA itself plays an important role in the risk of contracting an infectious disease [49]. There is a high prevalence of multi-morbidity, such as depression, asthma, and/or COPD, in patients with RA, which can further impair the immune system [50]. Immunosuppressive medications, such as corticosteroids, azathioprine, cyclophosphamide, or tumor necrosis factor inhibitors, which are used for the treatment of RA, are also associated with an increased risk of infections [35, 49]. This latter association has been investigated for HZ in an earlier study, which reported that the highest risk for HZ infections was associated with former cyclophosphamide use (OR 3.17) [51].

Numerous international studies have investigated whether diabetes mellitus is a risk factor for HZ. In accordance with the results presented here, several studies have shown that younger patients with diabetes appear to have an increased risk of HZ when compared to older patients with diabetes [13, 39, 41, 43]. For example, Forbes et al. found that those with the strongest association between HZ and DMT1 (OR 1.51) and HZ and DMT2 (OR 1.22) were those aged less than 50 years [13]. A number of studies have examined the association between HZ and diabetes and shown contradictory results [16, 18, 41]. The varying risk for HZ across studies can be due to different methodological aspects (i.e., the underlying definition of age groups for patients younger than 50 years, or adjustments for age and comorbidities); for example, one study showed that diabetes patients with high glycated hemoglobin (HbA1c) and aged less than 45 years have an increased risk for HZ [43]. However, laboratory data are usually only available in primary data studies.

The observation of increased risk for HZ in patients with depression is consistent with results reported in international literature, as reported in a recent meta-analysis (relative risk 1.23) [48]. A retrospective case–control study based on UK primary care data showed that patients with depression younger than 50 years are at a higher risk for developing HZ (OR 1.24) [13]. Two other studies also observed an increased risk in patients with depression, but did not include different age groups in their analysis [34, 45]. Although there seems to be an association between depression and risk of HZ, the explanation still remains unclear. It is possible that there is a decreased and dysregulated cell-mediated immunity in patients with depression, as it has been shown that depression is associated with reduced lymphocyte proliferation and decreased proportions of lymphocytes and T-cells [44]. Irwin et al. support this association by showing that VZV-specific responder cell frequency, a marker for cell-mediated immunity, is especially reduced in older patients with major depressive disorders [52, 53]. The observed association for younger age groups and their cell-mediated immunity as well as their specific risk for HZ requires further research.

The data show that COPD and asthma patients had a significantly higher risk of HZ when using systemic corticosteroids. The increased risk for HZ in these patients may be explained by the immunosuppressive effect of corticosteroids, resulting in COPD and asthma patients being susceptible to infectious diseases. Systemic corticosteroids are associated with negative effects on immunity, including the inhibition of inflammatory cytokines, reduction of antigen-presenting cells, and decrease of T-cells [33], consequently increasing the susceptibility to infections.

Recurrence rates for HZ have been previously reported by other authors, yet differences in study designs, study populations, and length of follow-up makes it difficult to compare results [18, 19, 54‐57]. Furthermore, there are no other studies reporting the risk for a second recurrence or recurrence for patients with UCs. However, a recent study from Spain reported significantly higher recurrence rates in immunocompromised patients [58]. This result is in line with the results presented here which show that patients with UCs have a higher risk of recurrence. Kim et al. reported overall recurrence rates of 12.0 per 1000 PY [18], and Tseng et al. reported a 10-year cumulative recurrence rate of 10.26% [54]. Similar to the results in this study, these authors observed a higher probability of recurrence in younger age groups compared to older adults. In the present study, this effect is even more pronounced in patients with at least one UC.

The study presented here has a number of limitations. It must be considered that the underlying data are collected for billing purposes. In the literature, the potential for upcoding is discussed for some of the considered UCs [59] and, therefore, it is possible that the risk of HZ in patients with UC is overestimated. An increased likelihood of receiving a diagnosis of HZ, for example, might result from regular visits to a general practitioner for a chronic condition. It is reasonable to assume that most patients with HZ would make an appointment with their general practitioner owing to the extensive rash and considerable pain associated with HZ, and also because everyone living in Germany has healthcare insurance. Furthermore, laboratory confirmation is missing and, therefore, other diagnoses cannot be ruled out, mainly zosteriform herpes simplex, which is especially relevant for recurrent HZ as it is associated with milder clinical symptoms than primary HZ [19]. Also, a number of risk-modifying factors for HZ incidence, such as the Hb1Ac value or other morbidity-associated laboratory parameters, cannot be captured in the claims database. Another limitation of the study is that it was not possible to adjust the data for some factors that may have affected the prevalence of considered UCs, including smoking, alcohol consumption, physical activity, and dietary habits. In addition to clinical aspects of risk-modifying factors, UC may also adversely impact the QoL in patients suffering from HZ. However, effects on QoL could not be assessed in the present study based on the available data. As the database is limited to one SHI and individuals in Germany self-select their SHI, it is important to assess the representativeness of the database. A comparison with national population statistics shows that those insured by BARMER are representative in terms of age and gender, as confirmed by national health technology assessment institutions [60].

The standard use of a vaccine for the prevention of HZ has recently been recommended by the German Standing Committee on Vaccination (STIKO) in immunocompetent adults older than 60 years and for adults older than 50 years with increased health risks due to an UC (e.g., human immunodeficiency virus, RA, lupus, COPD, asthma, and diabetes) [27].⁴ There is no vaccination recommendation for patients with depression under the age of 60 years, who were identified as having a significantly increased HZ risk. The results of this study could be incorporated into national treatment guidelines and structured DMPs to support optimal treatment and higher vaccination coverage in populations with UC. Considering the differing results in the literature, further research is needed on the observed risk in persons with diabetes. For this purpose, data from DMPs would be useful as clinical and laboratory variables are recorded there. Additionally, the underlying pathogenetic mechanism for the observed risks in underlying depression need further investigation. In addition to the inclusion of clinical parameters, the differentiation of other age groups can also provide information on specific risk constellations.